Unknown

Dataset Information

0

Modulating the skin mycobiome-bacteriome and treating seborrheic dermatitis with a probiotic-enriched oily suspension.


ABSTRACT: Seborrheic dermatitis (SD) affects 2-5% of the global population, with imbalances in the skin microbiome implicated in its development. This study assessed the impact of an oily suspension containing Lactobacillus crispatus P17631 and Lacticaseibacillus paracasei I1688 (termed EUTOPLAC) on SD symptoms and the skin mycobiome-bacteriome modulation. 25 SD patients were treated with EUTOPLAC for a week. Symptom severity and skin mycobiome-bacteriome changes were measured at the start of the treatment (T0), after seven days (T8), and three weeks post-treatment (T28). Results indicated symptom improvement post-EUTOPLAC, with notable reductions in the Malassezia genus. Concurrently, bacterial shifts were observed, including a decrease in Staphylococcus and an increase in Lactobacillus and Lacticaseibacillus. Network analysis highlighted post-EUTOPLAC instability in fungal and bacterial interactions, with increased negative correlations between Malassezia and Lactobacillus and Lacticaseibacillus genera. The study suggests EUTOPLAC's potential as a targeted SD treatment, reducing symptoms and modulating the mycobiome-bacteriome composition.

SUBMITTER: Truglio M 

PROVIDER: S-EPMC10834955 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Modulating the skin mycobiome-bacteriome and treating seborrheic dermatitis with a probiotic-enriched oily suspension.

Truglio Mauro M   Sivori Francesca F   Cavallo Ilaria I   Abril Elva E   Licursi Valerio V   Fabrizio Giorgia G   Cardinali Giorgia G   Pignatti Marco M   Toma Luigi L   Valensise Floriana F   Cristaudo Antonio A   Pimpinelli Fulvia F   Di Domenico Enea Gino EG  

Scientific reports 20240201 1


Seborrheic dermatitis (SD) affects 2-5% of the global population, with imbalances in the skin microbiome implicated in its development. This study assessed the impact of an oily suspension containing Lactobacillus crispatus P17631 and Lacticaseibacillus paracasei I1688 (termed EUTOPLAC) on SD symptoms and the skin mycobiome-bacteriome modulation. 25 SD patients were treated with EUTOPLAC for a week. Symptom severity and skin mycobiome-bacteriome changes were measured at the start of the treatmen  ...[more]

Similar Datasets

| PRJEB66726 | ENA
| S-EPMC7321695 | biostudies-literature
| S-EPMC5722561 | biostudies-literature
| S-EPMC11909108 | biostudies-literature
| S-EPMC11333864 | biostudies-literature
| S-EPMC9769585 | biostudies-literature
| S-EPMC7549904 | biostudies-literature
| S-EPMC9732001 | biostudies-literature
| S-EPMC5442261 | biostudies-literature
| S-EPMC9304052 | biostudies-literature